Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lipson

Showing results (171-180 of 249) with videos related to

Pageof 25
Sort By:
Therapeutic Advances in Respiratory Disease|May 29, 2020
Early and sustained symptom improvement with umeclidinium/vilanterol <i>versus</i> monotherapy in COPD: a <i>post hoc</i> analysis of the EMAX randomised controlled trialEdward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 8, 2021
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX TrialLeif Bjermer, Isabelle H Boucot, François Maltais, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 10, 2021
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPDJean Bourbeau, Mona Bafadhel, Neil C Barnes, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 11, 2023
Any Decrease in Lung Function is Associated With Worse Clinical Outcomes: Post Hoc Analysis of the IMPACT Interventional TrialMeiLan K Han, Gerard J Criner, David M G Halpin, et al.
Chronic Respiratory Disease|October 6, 2023
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?Edward M Kerwin, Paul W Jones, Leif H Bjermer, et al.
Respiratory Medicine|July 8, 2022
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPDFrançois Maltais, Claus F Vogelmeier, Edward M Kerwin, et al.
Digestive Diseases and Sciences|July 4, 1998
Giant gastric ulcers and risk factors for gastroduodenal mucosal disease in orthotopic lung transplant patientsD A Lipson, J A Berlin, H I Palevsky, et al.
American Journal of Respiratory and Critical Care Medicine|April 1, 2022
International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical TrialsPeter M A Calverley, Fernando J Martinez, Jørgen Vestbo, et al.
American Journal of Respiratory and Critical Care Medicine|May 24, 2017
Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease"David A Lipson, Helen Barnacle, Ruby Birk, et al.
Therapeutic Advances in Respiratory Disease|October 30, 2020
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACTJosé M Marín, Luis Mateos, Juan Roldán, et al.
Pageof 25

Showing results (171-180 of 249) with videos related to

Sort By:
Pageof 25
Therapeutic Advances in Respiratory Disease|May 29, 2020
Early and sustained symptom improvement with umeclidinium/vilanterol <i>versus</i> monotherapy in COPD: a <i>post hoc</i> analysis of the EMAX randomised controlled trialEdward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 8, 2021
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX TrialLeif Bjermer, Isabelle H Boucot, François Maltais, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 10, 2021
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPDJean Bourbeau, Mona Bafadhel, Neil C Barnes, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 11, 2023
Any Decrease in Lung Function is Associated With Worse Clinical Outcomes: Post Hoc Analysis of the IMPACT Interventional TrialMeiLan K Han, Gerard J Criner, David M G Halpin, et al.
Chronic Respiratory Disease|October 6, 2023
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?Edward M Kerwin, Paul W Jones, Leif H Bjermer, et al.
Respiratory Medicine|July 8, 2022
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPDFrançois Maltais, Claus F Vogelmeier, Edward M Kerwin, et al.
Digestive Diseases and Sciences|July 4, 1998
Giant gastric ulcers and risk factors for gastroduodenal mucosal disease in orthotopic lung transplant patientsD A Lipson, J A Berlin, H I Palevsky, et al.
American Journal of Respiratory and Critical Care Medicine|April 1, 2022
International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical TrialsPeter M A Calverley, Fernando J Martinez, Jørgen Vestbo, et al.
American Journal of Respiratory and Critical Care Medicine|May 24, 2017
Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease"David A Lipson, Helen Barnacle, Ruby Birk, et al.
Therapeutic Advances in Respiratory Disease|October 30, 2020
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACTJosé M Marín, Luis Mateos, Juan Roldán, et al.
Pageof 25